Applicant: Bonnert Attorney's Docket No.: 06275-450US1 / 100839-1P US

Serial No.: To Be Assigned Filed : Herewith

Page : 3 of 8

# Amendments to the Claims:

This listing of claims replaces all prior versions and listings of claims in the application:

# Listing of Claims:

1. (Original) A compound of formula (I) and pharmaceutically acceptable salts or solvates thereof:

### 2. (Cancelled)

(Currently amended) A method of treating asthma, allergic rhinitis, COPD, inflammatory 3. bowel disease, osteoarthritis, osteoporosis, rheumatoid arthritis, or psoriasis comprising administering a compound, pharmaceutically acceptable salt, solvate or in vivo hydrolysable ester thereof according to claim 1-for use as a medicament for the treatment of asthma, allergic rhinitis, COPD, inflammatory bowel disease, osteoarthritis, osteoporosis, rheumatoid-arthritis, or psoriasis.

Applicant: Bonnert Attorney's Docket No.: 06275-450US1 / 100839-1P US

Serial No.: To Be Assigned

Filed : Herewith Page : 4 of 8

4. (Currently amended) A <u>method of treating cancer comprising administering a compound</u>, pharmaceutically acceptable salt, solvate or *in vivo* hydrolysable ester thereof according to claim 1 for use as a medicament for the treatment of cancer.


# 5. (Cancelled)

- 6. (Currently amended) A method of treating a chemokine mediated disease wherein the chemokine binds to one or more chemokine receptors, which comprises administering to a patient a therapeutically effective amount of a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, as claimed in claim 1.
- 7. (Currently amended) A method of treating an inflammatory disease in a patient suffering from, or at risk of, said disease, which comprises administering to the patient a therapeutically effective amount of a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, as claimed in claim 1.
- 8. (Currently amended) A method of treating a disease in which angiogenesis is associated with raised CXCR2 chemokine levels, in a patient suffering from, or at risk of, said disease, which comprises administering to the patient a therapeutically effective amount of a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, as claimed in claim 1.
- 9. (Original) A process for the preparation of a compound of formula (I) which comprises reaction of a compound of formula (II):

Applicant: Bonnert Attorney's Docket No.: 06275-450US1 / 100839-1P US

Serial No.: To Be Assigned Filed : Herewith

Page : 5 of 8



where R is  $C_{1-6}$  alkyl with an acid, and optionally thereafter forming a pharmaceutically acceptable salt.

#### 10. (Cancelled)

- 11. (Currently amended) A method combination therapy as claimed in claim 10 for the treatment of asthma, allergic rhinitis, COPD, inflammatory bowel disease, irritable bowel syndrome, osteoarthritis, osteoporosis, rheumatoid arthritis, or psoriasis, comprising administering a compound of claim 1, formula (1) or a pharmaceutically acceptable salt, solvate or in vivo hydrolysable ester thereof, or a pharmaceutical composition or formulation comprising a compound of claim 1, formula (1), concurrently or sequentially with another therapy and/or another pharmaceutical agent.
- 12. (Currently amended) A method combination therapy as claimed in claim 10 for the treatment of cancer, comprising administering a compound of claim 1, formula (1) or a pharmaceutically acceptable salt, solvate or in vivo hydrolysable ester thereof, or a pharmaceutical composition or formulation comprising a compound of claim 1, formula (1), concurrently or sequentially with another therapy and/or another pharmaceutical agent.

Applicant: Bonnert Attorney's Docket No.: 06275-450US1 / 100839-1P US Serial No.: To Be Assigned

Filed : Herewith
Page : 6 of 8

13. (Currently amended) A pharmaceutical composition comprising a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, as claimed in claim 1 in association with and a pharmaceutically acceptable adjuvant, diluent or carrier.

- 14. (Currently amended) A method of treating pharmaceutical composition as claimed in claim 13 for the treatment of asthma, allergic rhinitis, COPD, inflammatory bowel disease, irritable bowel syndrome, osteoarthritis, osteoporosis, rheumatoid arthritis, or psoriasis comprising administering a pharmaceutical composition comprising a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, as claimed in claim 1 and a pharmaceutically acceptable adjuvant, diluent or carrier.
- 15. (Currently amended) A method of treating pharmaceutical composition as claimed in claim 13 for the treatment of cancer comprising administering a pharmaceutical composition comprising a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, as claimed in claim 1 and a pharmaceutically acceptable adjuvant, diluent or carrier.
- 16. (Currently amended) A process for the preparation of a pharmaceutical composition as elaimed in claim 13 comprising a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, as claimed in claim 1 in association with and a pharmaceutically acceptable adjuvant, diluent or carrier, which comprises the method comprising mixing a the compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, as claimed in claim 1 with a the pharmaceutically acceptable adjuvant, diluent or carrier.
- 17. (New) A composition comprising a compound of claim 1, formula (1) or a pharmaceutically acceptable salt, solvate or *in vivo* hydrolysable ester thereof, or a pharmaceutical composition or formulation comprising a compound of claim 1, formula (1), and an agent for the treatment of asthma, allergic rhinitis, COPD, inflammatory bowel disease, irritable bowel syndrome, osteoarthritis, osteoporosis, rheumatoid arthritis, or psoriasis.

Applicant: Bonnert

Serial No.: To Be Assigned

Filed : Herewith

Page : 7 of 8

(New) A composition comprising a compound of claim 1, formula (1) or a 18. pharmaceutically acceptable salt, solvate or in vivo hydrolysable ester thereof, or a pharmaceutical composition or formulation comprising a compound of claim 1, formula (1), and an agent for the treatment of cancer.

Attorney's Docket No.: 06275-450US1 / 100839-1P US